Lenalidomide

• Description:

  Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

• Product Name Alternative:

  CC-5013

• UNSPSC:

  12352005

• Hazard Statement:

  H361, H373

• Target:

  Apoptosis; Ligands for E3 Ligase; Molecular Glues

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Lenalidomide.html

• Purity:

  99.98

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=CC=CC(N)=C2CN1C(C(N3)=O)CCC3=O

• Molecular Formula:

  C13H13N3O3

• Molecular Weight:

  259.26

• Precautions:

  H361, H373

• References & Citations:

  [1]Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.|[2]Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36.|[3]Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26 (11) :2326-35.|[4]Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14 (4) :872-82.|[5]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175 (1) :171-185.e25.|[6]Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1.|[7]Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3 (7) :e941742.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Cereblon

• Citation 01:

  ACS Omega. 2024 Dec 3;9 (50) :49739-49748.|ACS Pharmacol Transl Sci. 2021 Feb 26;4 (2) :941-952.|Acta Pharmacol Sin. 2020 Sep;41 (9) :1246-1254.|Acta Pharmacol Sin. 2025 Aug;46 (8) :2296-2309.|Am J Pathol. 2015 Jun;185 (6) :1783-94. |Biochim Biophys Acta Mol Basis Dis. 2022 Oct 1;1868 (10) :166472.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|bioRxiv. 2024 June 12.|bioRxiv. 2024 October 19.|bioRxiv. April.|Cancer Cell. 2022 Nov 14;40 (11) :1294-1305.e4.|Cancer Res. 2025 Jan 2;85 (1) :101-117.|Cancer Sci. 2019 Dec;110 (12) :3802-3810.|Cancers (Basel) . 2024 Mar 28, 16 (7), 1319.|Cell Rep Med. 2024 Mar 19;5 (3) :101472.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2024 May 8;43 (5) :114211.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell. 2018 Sep 20;175 (1) :171-185.e25.|Chemrxiv. 2025 Nov 17.|Clin Chim Acta. 2024 Jan 15:553:117707.|Elife. 2018 Aug 1;7:e38430. |Eur J Pharmacol. 2025 Dec 5:1008:178303.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Faculty of Science, Masaryk University. Department of Experimental Biology.2014. |Food Chem Toxicol. 2019 Mar:125:392-402.|Free Radic Biol Med. 2023 Jul:203:86-101.|Front Cell Infect Microbiol. 2022 Jul 28;12:954814.|Harvard Medical School LINCS LIBRARY|Harvard University. 2025.|Inflammation. 2019 Feb;42 (1) :221-234. |Int Immunopharmacol. 2025 May 14:158:114831.|Int J Mol Sci. 2023 Sep 14;24 (18) :14097.|iScience. 2022 Jul 19;25 (8) :104781.|J Transl Med. 2024 Dec 3;22 (1) :1095.|Leukemia. 2025 Mar;39 (3) :720-733.|Microbiome. 2025 Feb 28;13 (1) :56.|Mol Ther Oncol. 2025 Feb 20;33 (1) :200952.|Nat Cancer. 2022 May;3 (5) :595-613.|Nat Chem Biol. 2021 Jun;17 (6) :711-717.|Nat Commun. 2017 May 22;8:15398. |Nat Commun. 2025 Nov 6;16 (1) :9805.|Nat Commun. 2025 Sep 1;16 (1) :8155.|Nature. 2024 Sep;633 (8030) :670-677.|Neoplasia. 2025 Oct 27:70:101243.|Oncol Rep. 2018 Jun;39 (6) :2873-2880. |Oxid Med Cell Longev. 2021 Dec 29:2021:8302831.|Patent. US20170360780A1.|Patent. US20180263995A1.|Patent. US20210379039A1.|Patent. US20220332776A1.|Patent. US20240261246A1.|Universidad de Navarra. 2024 Feb 28.|University of Washington. The Columbian College of Arts and Sciences. August 31, 2021.|Cell Commun Signal. 2025 May 7;23 (1) :216.|Food Chem Toxicol. 2019 Mar:125:392-402.

• CAS Number:

  [191732-72-6]